Sumanta Pal: The NCI Cooperative Groups are Addressing Clinically Relevant Questions for Agents Already in Use
Sumanta Pal, Vice Chair of Academic Affairs at City of Hope, shared a post on X:
“Congrats to Mehmet Asim Bilen for utilizing National Cancer Institute cooperative groups for what they are best at – addressing clinically relevant questions for agents already in our toolkit.
Excited to support the study he and Naomi Haas have put forward via ECOG-ACRIN Cancer Research Group looking at adj pembro in nccRCC.
Will try to encourage SWOG Cancer Research Network to get behind this!”
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared this post, adding:
“Would ‘echo’ Sumanta Pal and congratulate Mehmet Asim Bilen for leading this important P3 trial effort: adjuvant pembro vs surveillance for non clear cell RCC ECOG-ACRIN Cancer Research Group trying to build upon KN564.”
More posts featuring Sumanta Pal.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023